Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge.
BACKGROUND
We used the SIVmne model to examine the relative immunogenicity and protective efficacy of vaccines derived from temporal isolates of lentivirus infection. SIVmne170 is a molecular clone isolated from a pig-tailed macaque 170 weeks after inoculation with SIVmneCL8.


METHODS
We immunized pig-tailed macaques with Gag/Pol/Env vaccines derived from CL8 or 170 and examined their protective efficacy against CL8, 170, or chimeras 8/170 and 170/8, containing the 5' or 3' half of the respective parental genomes.


RESULTS
As expected, CL8 vaccines protected animals against the CL8, but not the 170 virus. Surprisingly, 170 vaccines not only failed to protect against the 170 virus, but also the less pathogenic CL8. Chimeric virus challenges revealed that the envelope antigen of CL8 represents an important target for protective immunity.


CONCLUSIONS
These results underscore the potential importance of targeting transmitted viruses through judicious choice of immunogens from early isolates for vaccine development.
Washington National Primate Research Center, University of Washington, Seattle, WA, USA.
Patricia
P
Polacino
Brad
B
Cleveland
Yongde
Y
Zhu
Jason T
JT
Kimata
Julie
J
Overbaugh
David
D
Anderson
Shiu-Lok
SL
Hu
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015686:Gene Products, env / Q000276:immunology; D015683:Gene Products, gag / Q000276:immunology; D015684:Gene Products, pol / Q000276:immunology; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000097:blood; D008254:Macaca nemestrina; D012367:RNA, Viral / Q000737:chemistry / Q000235:genetics; D012191:Retroviridae Proteins / Q000235:genetics / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology; D019562:Viral Load
D000914:Antibodies, Viral; D015686:Gene Products, env; D015683:Gene Products, gag; D015684:Gene Products, pol; D012367:RNA, Viral; D012191:Retroviridae Proteins; D018449:SAIDS Vaccines; D014614:Vaccines, Synthetic; D007371:Interferon-gamma